Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma * Bone metastases confirmed by bone scan * Current androgen deprivation therapy * Castration-resistant disease based on progression in bone and/or PSA progression * Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events * Life expectancy of greater than 3 months * Normal organ and marrow function * Capable of understanding and complying with the protocol requirements * Agree to use medically accepted methods of contraception * Able to swallow capsules Exclusion Criteria: * More than two prior chemotherapy regimens for metastatic prostate cancer * Known untreated, symptomatic or uncontrolled brain metastases * Serious or unhealed wound * Treatment with anticoagulants * Previously identified allergy or hypersensitivity to components of the study treatment formulation * History of a different malignancy unless disease-free for at least 5 years, or basal or squamous cell carcinoma of the skin * Current antiretroviral therapy * Uncontrolled hypertension * Uncontrolled intercurrent illness